Transient elastography for diagnosis of stages of hepatic fibrosis and cirrhosis in people with alcoholic liver disease

CS Pavlov, G Casazza, D Nikolova… - Cochrane Database …, 2015 - cochranelibrary.com
Background The presence and progression of hepatic (liver) fibrosis into cirrhosis is a
prognostic variable having impact on survival in people with alcoholic liver disease. Liver …

Treatment for hepatorenal syndrome in people with decompensated liver cirrhosis: a network meta‐analysis

LMJ Best, SC Freeman, AJ Sutton… - Cochrane Database …, 2019 - cochranelibrary.com
Background Hepatorenal syndrome is defined as renal failure in people with cirrhosis in the
absence of other causes. In addition to supportive treatment such as albumin to restore fluid …

Antibiotic prophylaxis to prevent spontaneous bacterial peritonitis in people with liver cirrhosis: a network meta‐analysis

O Komolafe, D Roberts, SC Freeman… - Cochrane database …, 2020 - cochranelibrary.com
Background Approximately 2.5% of all hospitalisations in people with liver cirrhosis are for
spontaneous bacterial peritonitis. Spontaneous bacterial peritonitis is associated with …

Glucocorticosteroids for people with alcoholic hepatitis

CS Pavlov, DL Varganova, G Casazza… - Cochrane Database …, 2019 - cochranelibrary.com
Background Alcoholic hepatitis is a form of alcoholic liver disease characterised by
steatosis, necroinflammation, fibrosis, and complications to the liver. Typically, alcoholic …

[HTML][HTML] The effects of intermittent hypoxic–hyperoxic exposures on lipid profile and inflammation in patients with metabolic syndrome

AB Afina, SG Oleg, AB Alexander, D Ines… - Frontiers in …, 2021 - frontiersin.org
Background: Patients with metabolic syndrome (MS) tend to suffer from comorbidities, and
are often simultaneously affected by obesity, dysglycemia, hypertension, and dyslipidemia …

Effectiveness of phosphatidylcholine as adjunctive therapy in improving liver function tests in patients with non-alcoholic fatty liver disease and metabolic …

IV Maev, AA Samsonov, LK Palgova… - BMJ open …, 2020 - bmjopengastro.bmj.com
Objective Non-alcoholic fatty liver disease (NAFLD) is the most common cause of abnormal
results of liver function tests. Earlier research showed that polyenylphosphatidylcholine …

Lifestyle modifications for nonalcohol‐related fatty liver disease: a network meta‐analysis

E Buzzetti, A Linden, LMJ Best… - Cochrane Database …, 2021 - cochranelibrary.com
Background The prevalence of nonalcohol‐related fatty liver disease (NAFLD) varies
between 19% and 33% in different populations. NAFLD decreases life expectancy and …

[HTML][HTML] Effectiveness of phosphatidylcholine in alleviating steatosis in patients with non-alcoholic fatty liver disease and cardiometabolic comorbidities (MANPOWER …

IV Maev, AA Samsonov, LK Palgova… - BMJ Open …, 2020 - bmjopengastro.bmj.com
Objective The concept of using naturally occurring compounds such as
polyenylphosphatidylcholine (PPC) as an adjunctive therapy to treat non-alcoholic fatty liver …

Treatment for bleeding oesophageal varices in people with decompensated liver cirrhosis: a network meta‐analysis

D Roberts, LMJ Best, SC Freeman… - Cochrane Database …, 2021 - cochranelibrary.com
Background Approximately 40% to 95% of people with liver cirrhosis have oesophageal
varices. About 15% to 20% of oesophageal varices bleed within about one to three years …

Ultrasonography for diagnosis of alcoholic cirrhosis in people with alcoholic liver disease

CS Pavlov, G Casazza, M Semenistaia… - Cochrane Database …, 2016 - cochranelibrary.com
Background Heavy alcohol consumption causes alcoholic liver disease and is a causal
factor of many types of liver injuries and concomitant diseases. It is a true systemic disease …